The vaccine from Janssen (Johnson & Johnson) is less effective against the Delta variant of the coronavirus, according to the preliminary results of a study published and cited in particular in the New York Times.
This vaccine, also administered in Belgium and which requires only one dose, generates relatively few antibodies against the Delta variant. Researchers at New York University conclude that it produces about five times less of the antibodies that protect against this mutation in the virus.
“We hope that in the future it will be possible to obtain a second injection”
“We don’t want to discourage people from benefiting from the Janssen vaccine, but we hope that in the future it will be possible to get a second injection, either by Janssen himself, or by Pfizer or Moderna”New York University virologist Nathaniel Landau, who led the study, told The New York Times.
The Pfizer and Moderna vaccines, which require two doses, also produced relatively fewer antibodies against the Delta variant according to the study, but this difference would be smaller than for the Janssen vaccine.
US health officials reported on Tuesday that 83% of new coronavirus cases in the US are attributed to the Delta variant. At the start of the month, this proportion was still only 50%. In Belgium, the Delta variant represented 66% of coronavirus contaminations in mid-July.